InvestSMART

Clarity Pharmaceuticals Ltd (ASX:CU6)

ALERT: Price-sensitive ASX Announcement for CU6
Current share price for CU6 : $2.420 -0.71 (-22.68%)+
Announcement
Release
14 Apr 2026 8:33AM
Price at Release
$3.130
Full Release
download
Summary
Clarity Pharmaceuticals Ltd, a clinical-stage radiopharmaceutical company, announced the signing of a Commercial Manufacturing Agreement with Nucleus RadioPharma for the production of 64Cu-SAR-bisPSMA. The agreement involves manufacturing at Nucleus's facilities in Rochester, Minnesota, and the future site in Spring House, Pennsylvania, with a combined capacity of up to 650,000 doses per year. This agreement is a strategic move to enhance Clarity's manufacturing capabilities in anticipation of the commercial launch of 64Cu-SAR-bisPSMA after the completion of Phase III trials and regulatory approvals. The partnership aims to support Clarity's large-scale rollout strategy, leveraging existing supply agreements and manufacturing frameworks.
Key Points
  • Clarity Pharmaceuticals has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA.
  • The agreement includes manufacturing capabilities at facilities in Rochester, Minnesota, and a future site in Spring House, Pennsylvania.
  • These facilities can produce up to 650,000 doses of 64Cu-SAR-bisPSMA annually.
  • The agreement builds on existing partnerships and supply agreements to support Clarity's manufacturing strategy.
  • The aim is to prepare for a large-scale commercial rollout of 64Cu-SAR-bisPSMA post successful completion of Phase III trials and FDA approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.